This company has been marked as potentially delisted and may not be actively trading. NASDAQ:INSY INSYS Therapeutics (INSY) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About INSYS Therapeutics Stock (NASDAQ:INSY) 30 days 90 days 365 days Advanced Chart Get INSYS Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.23▼$65,799,000.0052-Week Range N/AVolumeN/AAverage Volume9.52 million shsMarket Capitalization$21.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewInsys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.Read More… Receive INSY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INSYS Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address INSY Stock News HeadlinesFederal Indictment Against NJ Doctor Collapses in Stunning DOJ Reversal, as Obtained by Health Law AllianceMay 21 at 10:30 PM | morningstar.comLarge Granular Lymphocyte Leukemia Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsightApril 23, 2025 | theglobeandmail.comTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?May 24, 2025 | Augusta Precious Metals (Ad)Carcinoid Tumor Syndrome Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsightApril 15, 2025 | theglobeandmail.comAlly Financial Inc. (ALLY): Among the Dividend Giants with Lowest Short Interest in 2024September 25, 2024 | msn.comARS Pharmaceuticals: A Decent Bet For Upside After Neffy ApprovalSeptember 6, 2024 | seekingalpha.comMore than half a billion opioid pills in 14 years: How prescriptions contributed to a crisis in BaltimoreAugust 3, 2024 | msn.comAldeyra Therapeutics, Inc. (ALDX)May 7, 2024 | finance.yahoo.comSee More Headlines INSY Stock Analysis - Frequently Asked Questions How were INSYS Therapeutics' earnings last quarter? INSYS Therapeutics, Inc. (NASDAQ:INSY) released its quarterly earnings results on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.33. The business's revenue was down 68.1% compared to the same quarter last year. When did INSYS Therapeutics' stock split? INSYS Therapeutics shares split on the morning of Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly issued shares were payable to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of stock prior to the split would have 150 shares after the split. What other stocks do shareholders of INSYS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that INSYS Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Puma Biotechnology (PBYI), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Incyte (INCY) and BioMarin Pharmaceutical (BMRN). Company Calendar Last Earnings5/10/2019Today5/24/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:INSY Previous SymbolNASDAQ:NEOL CIK1516479 Webwww.insysrx.com Phone480-500-3127FaxN/AEmployees226Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,510,000.00 Net Margins-346.61% Pretax MarginN/A Return on Equity-1,430.37% Return on Assets-64.04% Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.50 Sales & Book Value Annual Sales$82.08 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / BookN/AMiscellaneous Outstanding Shares74,570,000Free FloatN/AMarket Cap$21.71 million OptionableOptionable Beta3.21 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:INSY) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredMemorial Day Sale! 82% Off Disruptors and Dominators!Jensen Huang recently gave the keynote speech at the Consumer Electronics Show in Las Vegas. When the Nvidi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INSYS Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INSYS Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.